Antiepileptic drugs: generic versus branded treatments
Dominic C Heaney, Josemir W Sander

Antiepileptic drugs (AEDs) are relatively cheap but high volumes of prescriptions mean that substantial drug-budget savings may be possible by switching from innovator brands to cheaper generic drugs. Such savings have been achieved in many other treatment areas. However, more caution may be needed in the case of epilepsy because of the  narrow therapeutic range of most AEDs; clinical principles of prescribing, which include making only cautious and  gradual changes to dosing; the health and socioeconomic impact of breakthrough seizures or toxicity; and the need Neurology and Neurosurgery for long-term consistency of supply. Many physicians and patient groups are insufficiently reassured by current  definitions of similarity between generics and innovator brands. Switching to the cheapest generic may offer drug-budget savings that outweigh any risk to patient safety. But to date, this cost-benefit analysis has not been done. We propose that all changes to established principles of treating epilepsy are evidence based and that the risks of switching are clearly defined.

 

Read More

Related Posts

SOAR Webinar

SOAR Webinar

**At this time, the SOAR study has reached capacity for conference participation. However, there still may be opportunities for research participation at the family conference due to cancellations or addition of other opportunities. If you would like to be placed on a...

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

The Dup15q Alliance is aware of the recent release by the FDA regarding Clonazepam Orally Disintegrating Tablets USP by Endo USA due to potential product carton strength mislabeling. Ongoing investigation identified the possibility that the affected clonazepam product...

Recall – Vigabatrin for Oral Solution USP

Recall – Vigabatrin for Oral Solution USP

TOPIC: Vigabatrin for Oral Solution USP, 500 mg by InvaGen Pharmaceuticals: Recall - Due to Leaking Sachets AUDIENCE: Patient, Health Professional, Pharmacy, Pediatric, Neurology ISSUE: InvaGen Pharmaceuticals is recalling one lot, NB301030, of Vigabatrin for Oral...